With over 9000 employees operating in 85 countries, Novartis Oncology has developed eight new practice-changing medicines in the past decade and has a broad pipeline of over 25 new molecular entities in development targeting key molecular pathways in cancer biology. The company is a segment of Novartis AG, which generates the majority of its revenue from its global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines, selling its products globally with the United States representing close to one third of total revenue.